Structural MRI images, 18F-FDG-PET and amyloid-PET images from 235 amyloid-positive patients and tau-PET images from 75 amyloid-positive patients, different from patients included in the maximal pathology sites selection samples, were randomly sub-sampled to generate 1000 independent training and test samples of regional patterns of Alzheimer’s disease biomarkers. The gene discussed is MAPT; the disease is Alzheimer disease.